Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01295645 · ClinicalTrials.gov registry record · Phase 2

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

A Phase 2 study of Transplantation Infection, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
27
Enrollment target
1
Study location

NCT01295645 is a Phase 2 study of Transplantation Infection that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants, below the 290-participant average among 4 other Transplantation Infection trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01295645, a Phase 2 study of Transplantation Infection, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if adding cidofovir to the standard of care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to standard of care alone. The safety of cidofovir will also be studied.

Conditions Studied

Interventions

  • DRUG Cidofovir
  • OTHER No Cidofovir

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-03-17
Est. Completion 2028-03-15
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT01295645

The ClinicalTrials.gov registry entry for NCT01295645 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 290-participant average among 4 other Transplantation Infection trials with a reported enrollment target (91% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Transplantation Infection appearing as the primary indexed condition, and to 2 interventions - of which Cidofovir is the first listed.

NCT01295645 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01295645 about?

NCT01295645 is a clinical study titled "Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis". The goal of this clinical research study is to learn if adding cidofovir to the standard of care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to standard of care alone. The safety of cidofovir will also be studied.

What is the current status of trial NCT01295645?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2011-03-17. Estimated completion is 2028-03-15.

What conditions does trial NCT01295645 study?

This clinical trial studies the following conditions: Transplantation Infection.

What interventions are being tested in trial NCT01295645?

The interventions under investigation include: Cidofovir (DRUG), No Cidofovir (OTHER).

Who is sponsoring clinical trial NCT01295645?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01295645 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Transplantation Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.